EP
RLAY icon

Eversept Partners’s Relay Therapeutics RLAY Stock Holding History

Eversept Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.13M Buy
434,314
+163,609
+60% +$2.38M 0.42% 56
2026
Q1 		$2.69M Sell
270,705
-218,432
-45% -$1.95M 0.14% 81
2025
Q4 		$4.14M Buy
489,137
+10,081
+2% +$71.9K 0.21% 74
2025
Q3 		$2.5M Sell
479,056
-54,353
-10% -$207K 0.17% 62
2025
Q2 		$1.85M Buy
+533,409
New +$1.59M 0.17% 54

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Eversept Partners's RLAY Position: Q2 2026 in Review

Eversept Partners increased its Relay Therapeutics (RLAY) stake by 60% in Q2 2026, buying an estimated $2.38M and bringing the position to 434,314 shares worth $8.13M. The position accounts for 0.42% of the portfolio, ranked #56.

Eversept Partners first reported a position in RLAY in Q2 2025 and has held it in 5 quarters since. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Eversept Partners held 434,314 shares of Relay Therapeutics worth $8.13M as of Q2 2026.
  • Eversept Partners bought 163,609 Relay Therapeutics shares in Q2 2026, an estimated $2.38M.
  • Relay Therapeutics made up 0.42% of Eversept Partners's portfolio in Q2 2026, its #56 holding.
  • Eversept Partners first reported a position in Relay Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.